KER-047
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Deficiency Anemia
Conditions
Iron Deficiency Anemia
Trial Timeline
Nov 30, 2023 → Jan 4, 2026
NCT ID
NCT05927012About KER-047
KER-047 is a phase 2 stage product being developed by Keros Therapeutics for Iron Deficiency Anemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05927012. Target conditions include Iron Deficiency Anemia.
What happened to similar drugs?
5 of 13 similar drugs in Iron Deficiency Anemia were approved
Approved (5) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05927012 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Iron Deficiency Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| H. pylori treatment | Eisai | Phase 2/3 | 38 |
| Deferasirox | Novartis | Phase 3 | 40 |
| CSJ137 + Placebo | Novartis | Phase 1 | 29 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 38 |
| Desferasirox | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Approved | 43 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 32 |
| ICL670 | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 40 |
| Z-213 | Zeria Pharmaceutical | Phase 3 | 40 |